Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Induction of Type I Interferon through a Noncanonical Toll-Like Receptor 7 Pathway during Yersinia pestis Infection.

Dhariwala MO, Olson RM, Anderson DM.

Infect Immun. 2017 Oct 18;85(11). pii: e00570-17. doi: 10.1128/IAI.00570-17. Print 2017 Nov.

2.

New Role for FDA-Approved Drugs in Combating Antibiotic-Resistant Bacteria.

Andersson JA, Fitts EC, Kirtley ML, Ponnusamy D, Peniche AG, Dann SM, Motin VL, Chauhan S, Rosenzweig JA, Sha J, Chopra AK.

Antimicrob Agents Chemother. 2016 May 23;60(6):3717-29. doi: 10.1128/AAC.00326-16. Print 2016 Jun.

3.

Environmental Regulation of Yersinia Pathophysiology.

Chen S, Thompson KM, Francis MS.

Front Cell Infect Microbiol. 2016 Mar 2;6:25. doi: 10.3389/fcimb.2016.00025. eCollection 2016. Review.

4.

Recombinant Bivalent Fusion Protein rVE Induces CD4+ and CD8+ T-Cell Mediated Memory Immune Response for Protection Against Yersinia enterocolitica Infection.

Singh AK, Kingston JJ, Gupta SK, Batra HV.

Front Microbiol. 2015 Dec 16;6:1407. doi: 10.3389/fmicb.2015.01407. eCollection 2015.

5.

Role of Tellurite Resistance Operon in Filamentous Growth of Yersinia pestis in Macrophages.

Ponnusamy D, Clinkenbeard KD.

PLoS One. 2015 Nov 4;10(11):e0141984. doi: 10.1371/journal.pone.0141984. eCollection 2015.

6.

Oral administration of a recombinant attenuated Yersinia pseudotuberculosis strain elicits protective immunity against plague.

Sun W, Sanapala S, Rahav H, Curtiss R 3rd.

Vaccine. 2015 Nov 27;33(48):6727-35. doi: 10.1016/j.vaccine.2015.10.074. Epub 2015 Oct 26.

7.

Yersinia pestis Requires Host Rab1b for Survival in Macrophages.

Connor MG, Pulsifer AR, Price CT, Abu Kwaik Y, Lawrenz MB.

PLoS Pathog. 2015 Oct 23;11(10):e1005241. doi: 10.1371/journal.ppat.1005241. eCollection 2015 Oct.

8.

Spatially distinct neutrophil responses within the inflammatory lesions of pneumonic plague.

Stasulli NM, Eichelberger KR, Price PA, Pechous RD, Montgomery SA, Parker JS, Goldman WE.

MBio. 2015 Oct 13;6(5):e01530-15. doi: 10.1128/mBio.01530-15.

9.

Further characterization of a highly attenuated Yersinia pestis CO92 mutant deleted for the genes encoding Braun lipoprotein and plasminogen activator protease in murine alveolar and primary human macrophages.

van Lier CJ, Tiner BL, Chauhan S, Motin VL, Fitts EC, Huante MB, Endsley JJ, Ponnusamy D, Sha J, Chopra AK.

Microb Pathog. 2015 Mar;80:27-38. doi: 10.1016/j.micpath.2015.02.005. Epub 2015 Feb 16.

10.

Caspase-3 mediates the pathogenic effect of Yersinia pestis YopM in liver of C57BL/6 mice and contributes to YopM's function in spleen.

Ye Z, Gorman AA, Uittenbogaard AM, Myers-Morales T, Kaplan AM, Cohen DA, Straley SC.

PLoS One. 2014 Nov 5;9(11):e110956. doi: 10.1371/journal.pone.0110956. eCollection 2014.

11.

Coregulation of host-adapted metabolism and virulence by pathogenic yersiniae.

Heroven AK, Dersch P.

Front Cell Infect Microbiol. 2014 Oct 20;4:146. doi: 10.3389/fcimb.2014.00146. eCollection 2014. Review.

12.

The impact of "omic" and imaging technologies on assessing the host immune response to biodefence agents.

Tree JA, Flick-Smith H, Elmore MJ, Rowland CA.

J Immunol Res. 2014;2014:237043. doi: 10.1155/2014/237043. Epub 2014 Sep 16. Review.

13.

LcrV delivered via type III secretion system of live attenuated Yersinia pseudotuberculosis enhances immunogenicity against pneumonic plague.

Sun W, Sanapala S, Henderson JC, Sam S, Olinzock J, Trent MS, Curtiss R 3rd.

Infect Immun. 2014 Oct;82(10):4390-404. doi: 10.1128/IAI.02173-14. Epub 2014 Aug 11.

14.

Multiple roles of Myd88 in the immune response to the plague F1-V vaccine and in protection against an aerosol challenge of Yersinia pestis CO92 in mice.

Dankmeyer JL, Fast RL, Cote CK, Worsham PL, Fritz D, Fisher D, Kern SJ, Merkel T, Kirschning CJ, Amemiya K.

J Immunol Res. 2014;2014:341820. doi: 10.1155/2014/341820. Epub 2014 Jun 4.

15.

TNFα and IFNγ but not perforin are critical for CD8 T cell-mediated protection against pulmonary Yersinia pestis infection.

Szaba FM, Kummer LW, Duso DK, Koroleva EP, Tumanov AV, Cooper AM, Bliska JB, Smiley ST, Lin JS.

PLoS Pathog. 2014 May 22;10(5):e1004142. doi: 10.1371/journal.ppat.1004142. eCollection 2014 May.

16.

Caspase-8 and RIP kinases regulate bacteria-induced innate immune responses and cell death.

Weng D, Marty-Roix R, Ganesan S, Proulx MK, Vladimer GI, Kaiser WJ, Mocarski ES, Pouliot K, Chan FK, Kelliher MA, Harris PA, Bertin J, Gough PJ, Shayakhmetov DM, Goguen JD, Fitzgerald KA, Silverman N, Lien E.

Proc Natl Acad Sci U S A. 2014 May 20;111(20):7391-6. doi: 10.1073/pnas.1403477111. Epub 2014 May 5.

17.

Deletion of Braun lipoprotein and plasminogen-activating protease-encoding genes attenuates Yersinia pestis in mouse models of bubonic and pneumonic plague.

van Lier CJ, Sha J, Kirtley ML, Cao A, Tiner BL, Erova TE, Cong Y, Kozlova EV, Popov VL, Baze WB, Chopra AK.

Infect Immun. 2014 Jun;82(6):2485-503. doi: 10.1128/IAI.01595-13. Epub 2014 Mar 31.

18.

Yersinia pestis: mechanisms of entry into and resistance to the host cell.

Ke Y, Chen Z, Yang R.

Front Cell Infect Microbiol. 2013 Dec 24;3:106. doi: 10.3389/fcimb.2013.00106. eCollection 2013. Review.

19.

Rational considerations about development of live attenuated Yersinia pestis vaccines.

Sun W, Curtiss R.

Curr Pharm Biotechnol. 2013;14(10):878-86. Review.

20.

Yersinia pestis survival and replication within human neutrophil phagosomes and uptake of infected neutrophils by macrophages.

Spinner JL, Winfree S, Starr T, Shannon JG, Nair V, Steele-Mortimer O, Hinnebusch BJ.

J Leukoc Biol. 2014 Mar;95(3):389-98. doi: 10.1189/jlb.1112551. Epub 2013 Nov 13.

Supplemental Content

Support Center